Animal Models as Surrogates, SBIR Phase I ^ RFP No. PHS 2010-1 Topic #13

该合同的目的是确定由于功能丧失突变而产生的有益表型，以确定可以在传统药物开发计划和治疗疾病中抑制的靶向蛋白质。Kineta将采用另一种策略，即利用现有的模式生物和遗传资源来识别药物替代突变（定义为赋予有益的、药物样的或健康表型的突变）。DS突变及其相关基因和基因产物是理想功能药物的蓝图。Kineta公司将开发一个药物代理本体，该本体将集成到现有的ncrr支持的资源中，以提供工具并明确支持药物发现。

The purpose of this contract is to identify beneficial phenotypes that are produced as a result of loss-of-function mutations to pinpoint proteins that can be targeted for inhibition in traditional drug development programs and treatment diseases. Kineta will use an alternative strategy that uses existing model organisms and genetic resources to identify Drug Surrogate Mutations (defined as mutations that confer beneficial, drug-like or health phenotypes). DS mutations and their associated genes and gene products serve as the blueprint for ideally functional drugs. Kineta, Inc. will develop a drug surrogate Ontology that will be integrated into existing NCRR-supported resources to provide tools and explicitly support drug discovery.